LifeCycle Pharma Announces New Product Candidate; Initiates Phase I Clinical Trial for Sirolimus

Company Announcement no. 30/2007                                                

To: OMX Nordic Exchange	      Hørsholm, Denmark, November 29, 2007 

  LifeCycle Pharma Announces New Product Candidate; Initiates Phase I Clinical  
   Trial for Sirolimus, an Immunosuppressant to Prevent Organ Rejection after   
      Transplantation and for the Treatment of Certain Autoimmune Diseases      

Hørsholm, Denmark, November 29, 2007; LifeCycle Pharma A/S (OMX: LCP) (the      
“Company” or “LCP”), an emerging specialty pharmaceutical company, today        
announced a new product candidate LCP-Siro. The active ingredient in LCP-Siro is
Sirolimus, an immunosuppressant for the prevention of organ rejection after     
transplantation and for the treatment of certain autoimmune diseases. The       
Company has also initiated a Phase I clinical trial for LCP-Siro in healthy     
volunteers. Data from the Phase I clinical trial is expected in 2008.           

The Company believes that by applying the same reformulation methodology as for 
LCP-Tacro, the Company's lead immunosuppressive product candidate, it can       
achieve a superior product profile with LCP-Siro, including increased           
bioavailability and reduced dosing.                                             

Sirolimus is today marketed by Wyeth under the brand name Rapamune®. Rapamune is
sold as an oral solution and tablet and coats the CYPHER coronary stent marketed
by Johnson & Johnson. Rapamune generates annual sales of approximately $400     
million.                                                                        

About LifeCycle Pharma A/S (“LCP”)                                              
LCP is an emerging specialty pharmaceuticals company that, through innovative   
technologies, is able to rapidly develop a portfolio of differentiated products 
to meet the unique needs of key therapeutic markets and patient populations.    
This includes products for immunosuppression, specifically organ                
transplantation, and to combat certain cardiovascular diseases.  By using its   
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the  
Company has a diversified near- and medium-term pipeline, including a product   
ready for US commercialization, five product candidates in clinical trials and  
three in preclinical stages of development. LCP is listed on the OMX Nordic     
Exchange under the trading symbol (OMX: LCP). For further information, please   
visit www.lcpharma.com.                                                         

Contact:                                                                        
Michael Wolff Jensen                                                            
EVP and CFO                                                                     
+45 4074-6244; MWJ@lcpharma.com                                                 

Francesca M. DeMartino	                                                         
Director, Investor Relations & Corporate Communications                         
(917) 747-4938; FDM@lcpharma.com                                                
                                  ---oo0oo---